Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Jianghong Fan"'
Autor:
Fang Wu, Youssef Mousa, Kimberly Raines, Chris Bode, Yu Chung Tsang, Rodrigo Cristofoletti, Hongling Zhang, Tycho Heimbach, Lanyan Fang, Filippos Kesisoglou, Amitava Mitra, James Polli, Myong‐Jin Kim, Jianghong Fan, Banu S. Zolnik, Duxin Sun, Yi Zhang, Liang Zhao
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 5, Pp 585-597 (2023)
Abstract This report summarizes the proceedings for day 2 sessions 1 and 3 of the 2‐day public workshop entitled “Regulatory Utility of Mechanistic Modeling to Support Alternative Bioequivalence Approaches,” a jointly sponsored workshop by the
Externí odkaz:
https://doaj.org/article/bff355b182e94d38a6b888911c0d4a2e
Autor:
Xinyuan Zhang, Yuching Yang, Manuela Grimstein, Guansheng Liu, Eliford Kitabi, Jianghong Fan, Ying‐Hong Wang, Justin Earp, James L. Weaver, Hao Zhu, Jiang Liu, Kellie S. Reynolds, Shiew‐Mei Huang, Yaning Wang
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 9, Pp 973-982 (2021)
Abstract A critical step to evaluate the potential in vivo antiviral activity of a drug is to connect the in vivo exposure to its in vitro antiviral activity. The Anti–SARS‐CoV‐2 Repurposing Drug Database is a database that includes both in vit
Externí odkaz:
https://doaj.org/article/0cb77c809c824b32835bc7a4a70613b8
Autor:
Jia Gao, Jianghong Fan, Zhijun Meng, Rui Wang, Caihong Liu, Jing Liu, Bin Liang, Jing Wang, Yaoli Xie, Jing Zhao, Rui Guo, Jianli Zhao, Xinliang Ma, Xiangying Jiao, Jimin Cao, Yajing Wang
Publikováno v:
Cell Death and Disease, Vol 12, Iss 6, Pp 1-12 (2021)
Abstract There is limited and discordant evidence on the role of nicotine in diabetic vascular disease. Exacerbated endothelial cell dysregulation in smokers with diabetes is associated with the disrupted adipose function. Adipokines possess vascular
Externí odkaz:
https://doaj.org/article/8782054d7f7a4fc78ed3c6bc27029191
Autor:
Carrie German, Zhijian Chen, Andrzej Przekwas, Ross Walenga, Andrew Babiskin, Liang Zhao, Jianghong Fan, Ming-Liang Tan
Publikováno v:
Pharmaceutical Research. 40:961-975
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e919144e1ec34bbad5bf1e83c9df5bb5
https://doi.org/10.1007/s11095-023-03480-6
https://doi.org/10.1007/s11095-023-03480-6
Autor:
Justin C. Earp, Nan Zheng, Eliford Kitabi, Yuching Yang, Manuela Grimstein, Jiang Liu, Yaning Wang, Jianghong Fan, Hao Zhu, Youwei Bi, Xinyuan Zhang, Ye Xiong
Publikováno v:
Clinical Pharmacology & Therapeutics. 111:572-578
Leveraging limited clinical and nonclinical data through modeling approaches facilitates new drug development and regulatory decision making amid the coronavirus disease 2019 (COVID-19) pandemic. Model-informed drug development (MIDD) is an essential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70b1bae439e49cb05f4e0790a667ce7d
https://doi.org/10.1002/cpt.2491
https://doi.org/10.1002/cpt.2491
Autor:
Vikram Arya, Xinyuan Zhang, Justin C. Earp, Kellie S. Reynolds, Yaning Wang, Manuela Grimstein, Hao Zhu, Yuching Yang, Eliford Kitabi, Jianghong Fan
Publikováno v:
Clinical Pharmacology & Therapeutics. 111:624-634
Remdesivir (RDV) is the first drug approved by the US Food and Drug Administration (FDA) for the treatment of coronavirus disease 2019 (COVID-19) in certain patients requiring hospitalization. As a nucleoside analogue prodrug, RDV undergoes intracell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dbff2b27a48eab542615954b8b8f186
https://doi.org/10.1002/cpt.2445
https://doi.org/10.1002/cpt.2445
Autor:
Arup Kumar Sinha, Olen Stephens, Marc R. Theoret, Mei Ou, R. Pazdur, Gregory H. Reaman, Katherine Windsor, Yuching Yang, Suzanne Demko, Denise Casey, Kirsten B. Goldberg, Harpreet Singh, Abhilasha Nair, Jianghong Fan, Yuan Li Shen, Ruby Leong, Whitney S. Helms, M. Anwar Goheer, Byeongtaek Oh, Jiang Liu, Vishal Bhatnagar, Sachia Khasar, Selena R. Daniels, Stacy Shifflett Shord, Sharon Sickafuse, Lili Pan, Yuan Xu, Pallavi Mishra-Kalyani
Publikováno v:
Clinical Cancer Research. 27:4142-4146
On April 10, 2020, the FDA approved selumetinib (KOSELUGO, AstraZeneca) for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. Approval was based on dem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69c0965ed2e8a2628df56c33b22041b4
https://doi.org/10.1158/1078-0432.ccr-20-5032
https://doi.org/10.1158/1078-0432.ccr-20-5032
Autor:
Wei Chen, Marc R. Theoret, Pengfei Song, Xiao Hong Chen, Shenghui Tang, Kirsten B. Goldberg, Yutao Gong, Mallorie H. Fiero, Tiffany K. Ricks, William F. Pierce, Richard Pazdur, Joyce Cheng, Jianghong Fan, Fang Li, Mirat Shah, Suparna Wedam, Jingyu Yu, Laleh Amiri-Kordestani, Julia A. Beaver, Huiming Xia, Xinyuan Zhang
Publikováno v:
Clinical Cancer Research. 27:1220-1226
On April 17, 2020, the FDA approved tucatinib in combination with trastuzumab and capecitabine for the treatment of patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95b5af548dcf4feecdfc0fccfce1e385
https://doi.org/10.1158/1078-0432.ccr-20-2701
https://doi.org/10.1158/1078-0432.ccr-20-2701
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 2342
This chapter provides regulatory perspectives on how to translate in vitro drug metabolism findings into in vivo drug-drug interaction (DDI) predictions and how this affects the decision of conducting in vivo DDI evaluation. The chapter delineates ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c8597bda7e7a866801275a0f8228d3d3
https://pubmed.ncbi.nlm.nih.gov/34272707
https://pubmed.ncbi.nlm.nih.gov/34272707
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics. 142:153-164
The distribution of nanomedicines inside solid tumors is often restricted to perivascular areas, leaving most distal tumor cells out of reach. This partly explains modest patient benefit of many nanomedicines compared to their free-form counterparts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0df555f804a02bee6f0647ce812232ac
https://doi.org/10.1016/j.ejpb.2019.06.005
https://doi.org/10.1016/j.ejpb.2019.06.005